Peter M. Voorhees, MD
Although novel immunotherapy approaches have not proven to be curative in heavily pretreated patients with relapsed/refractory multiple myeloma, the strategy is resulting in unprecedented responses and progression-free survival (PFS) benefits, according to Peter Voorhees, MD.
“You can look at [CAR T-cell therapy] from either a 'glass half full' or 'glass half empty' perspective,” said Voorhees. “Glass half empty [means]: It's not curative, patients are still progressing, and the median PFS with, say, idecabtagene vicleucel (ide-cel; bb2121), was 12 months. On the other hand, [if we look at it from a] glass half full [perspective], then: We've never seen anything like this before in this group of patients. A median PFS of 12 months in this patient population is unheard of.”
Topline results from the pivotal phase II KarMMA trial (NCT03361748) showed that treatment with ide-cel resulted in a 73.4% overall response rate (ORR) in patients with relapsed/refractory disease, meeting the trial’s primary endpoint.1
Furthermore, the complete response (CR) rate with the BCMA-targeted CAR T-cell product was 31.3% and the median duration of response was 10.6 months.
... to read the full story